Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 295-304
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Table 2 Best response to treatment
| Response | Second-line, n = 22 | Salvage therapy, n = 19 | P value | |||
| Best response | ||||||
| Complete response | 0 | 0 | ||||
| Partial response | 2 | 0 | ||||
| Stable disease | 8 | 7 | ||||
| Progressive disease | 9 | 7 | ||||
| Unknown | 3 | 5 | ||||
| Objective response rate | 2 | (11) | 0 | (0) | 0.50 | |
| Disease control rate | 10 | (53) | 7 | (50) | 1.00 | |
- Citation: Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304
- URL: https://www.wjgnet.com/1948-5204/full/v13/i4/295.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i4.295